|
Palo Alto, CA, November 13, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that interim clinical data presentations on its
lead product candidates, TELCYTA™ (TLK286) and TELINTRA™
(TLK199), and results from selected preclinical and research programs
will be presented at the AACR-NCI-EORTC* Molecular Targets and Cancer
Therapeutics Conference in Boston.
Tuesday, November 18, 12:30 — 2:30
p.m.
- Identification and biochemical characterization of novel cRaf
inhibitors identified by TRAP™ computational discovery technology
- High efficiency screening: discovery of cancer drug leads with
Telik’s TRAP™ technology
Thursday, November 20, 12:30 — 2:30
p.m.
- Phase 1-2a study of TLK286 (TELCYTA™, a novel glutathione
analog) in combination with carboplatin in platinum refractory
or resistant (3rd line or greater) ovarian cancer
- Phase 1-2a dose ranging study of TLK286 (TELCYTA™, a novel
glutathione analog) in combination with docetaxel in platinum-resistant
non-small cell lung cancer
- Phase 1-2a dose ranging study of TLK286 (TELCYTA™, a novel
glutathione analog) in combination with Doxil® in platinum
refractory or resistant ovarian cancer
- Phase 1-2a dose ranging study of TLK199 (a novel glutathione
analog) in myelodysplastic syndrome
- Synergistic cancer cell cytotoxicity of TLK286 (TELCYTA™)
in combination with carboplatin, cisplatin, doxorubicin, docetaxel,
paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal
cancer cell lines
- TLK286 (TELCYTA™): mechanism of induction of apoptosis
in human cancer cells
- In vitro and in vivo pharmacokinetic characterization of TLK286
(TELCYTA™), a novel anti-tumor agent
* American Association of Cancer Research — National
Cancer Institute — European Organization for Research and
Treatment of Cancer
About Telik, Inc.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™. Telik’s product candidates were discovered
using its proprietary technology, TRAP, which enables the rapid
and efficient discovery of small molecule drug candidates. Additional
information is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding our ability to
successfully develop TELCYTA™ for the treatment of any cancer,
its tolerability, potential efficacy or market potential. Telik
can give no assurance with regard to these statements. None of our
products have been determined to be safe or effective in humans
or been approved for marketing. Substantial additional testing,
including randomized, controlled clinical trials of TELCYTA™
will be necessary prior to seeking marketing approval. There can
be no assurance that such trials will accrue sufficient patients,
be conducted with sufficient quality, in a timely manner, have a
successful outcome, or that regulatory approval will be obtained.
In addition, we are reliant on external manufacturing, and any interruption
or delay in drug supply could adversely affect the development program.
More detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Telik’s
periodic filings with the Securities and Exchange Commission. Telik
assumes no obligation to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
